Clinical Efficacy and Safety of Apatinib Combined with Irinotecan in HER2-negative Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First-Line Treatment Failure: A Single-Arm, Single-Center Retrospective Study

作者：Jiajia Huang, Jianjun Peng, Ertao Zhai, Ran Wei, Chen Qian, Jialin Li, Shirong Cai, Jin-ping Ma · 发表于：Journal of Gastrointestinal Cancer · 年份：2025 · DOI：10.1007/s12029-025-01259-z · 被引用次数：3 · 研究领域：Gastric Cancer Management and Outcomes、HER2/EGFR in Cancer Research、Esophageal Cancer Research and Treatment

BACKGROUND: In this study, the clinical efficacy and safety of apatinib combined with irinotecan in HER2-negative patients with first-line treatment failure for advanced gastric adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma were evaluated. METHODS: intravenously once every 3 weeks) plus oral apatinib (500 mg once daily on days 1-21 of each 3-week cycle), until disease progression, unacceptable toxicity, or death. The primary endpoints were progression-free survival (PFS) and overall survival (OS), which were calculated via the Kaplan‒Meier method. RESULTS: Between Feb 21, 2019, and Aug 14, 2023, 79 patients met the inclusion criteria. The median PFS was 3.20 months (95% CI, 1.57‒4.83), and the median OS was 7.60 months (95% CI, 5.11‒10.10). According to RECIST version 1.1, 15 patients (18.99%) achieved an objective response, and 31 patients (39.24%) achieved disease control. In terms of the safety profile, 72.2% of patients experienced treatment-emergent adverse events of any grade, among whom, 59.5% of patients experienced grade 1-2 adverse events and 12.7% of patients experienced grade 3-4 adverse events. CONCLUSION: Apatinib combined with irinotecan demonstrates modest efficacy with manageable safety profiles in HER2-negative patients with advanced gastric or GEJ adenocarcinoma for whom first-line treatment has failed. Further prospective studies are warranted.